Dronedarone STADA: Uses, Dosage & Side Effects
Antiarrhythmic medication for maintaining normal heart rhythm after atrial fibrillation
Quick Facts
Key Takeaways
- Dronedarone STADA (400 mg) is taken twice daily with meals to prevent recurrence of atrial fibrillation after cardioversion.
- It is contraindicated in permanent atrial fibrillation, heart failure, severe liver or kidney impairment, and when used with strong CYP3A4 inhibitors or QT-prolonging drugs.
- Unlike amiodarone, dronedarone has a shorter half-life (13–19 hours) and carries a lower risk of thyroid and lung toxicity.
- Regular monitoring of liver function, kidney function, and heart rhythm (ECG) is required during treatment.
- Must be taken with food to achieve adequate drug absorption — bioavailability increases substantially when taken with meals.
What Is Dronedarone STADA and What Is It Used For?
Dronedarone STADA contains the active substance dronedarone, a multichannel-blocking antiarrhythmic agent. It belongs to a group of medicines called antiarrhythmics, which help regulate the heart’s electrical activity. Dronedarone works by blocking sodium, potassium, and calcium ion channels in the heart, and also has antiadrenergic (beta-blocking) properties. This multi-pronged mechanism prolongs the cardiac action potential and refractory period, making it more difficult for abnormal heart rhythms to develop or persist.
Dronedarone STADA is specifically indicated for clinically stable adult patients with a history of, or current, non-permanent atrial fibrillation (AF) to prevent recurrence of AF or to lower the ventricular rate. It is prescribed after a procedure called cardioversion — either electrical or pharmacological — has successfully restored normal sinus rhythm. The goal of treatment is to keep the heart beating regularly and prevent the atrial fibrillation from coming back.
Atrial fibrillation is the most common sustained cardiac arrhythmia, affecting approximately 2–4% of the adult population worldwide. In AF, the upper chambers of the heart (the atria) beat irregularly and often rapidly, which can lead to symptoms such as palpitations, fatigue, dizziness, shortness of breath, and reduced exercise tolerance. Beyond symptoms, AF increases the risk of stroke by approximately fivefold and contributes to the development of heart failure. Maintaining sinus rhythm after cardioversion is therefore an important therapeutic goal for many patients.
Dronedarone was developed as a structural analogue of amiodarone, the most widely used antiarrhythmic agent. The key difference is that dronedarone lacks the iodine moiety found in amiodarone, which is responsible for many of amiodarone’s most troublesome side effects, including thyroid dysfunction, pulmonary fibrosis, and skin photosensitivity. As a result, dronedarone has a shorter elimination half-life (approximately 13–19 hours versus 40–55 days for amiodarone) and a more predictable pharmacokinetic profile. The landmark ATHENA trial demonstrated that dronedarone significantly reduced the composite endpoint of cardiovascular hospitalization or death in patients with paroxysmal or persistent AF.
Your doctor will consider all available treatment options before prescribing Dronedarone STADA. The choice of antiarrhythmic therapy depends on the type and frequency of arrhythmia, the presence of underlying heart disease, other medications you take, and individual risk factors. Dronedarone is generally considered when other treatments have been insufficient or when the patient’s clinical profile makes it a suitable first-line option for rhythm control, in line with current ESC and AHA guidelines for atrial fibrillation management.
What Should You Know Before Taking Dronedarone STADA?
Contraindications
Do not take Dronedarone STADA if any of the following conditions apply to you. These are absolute contraindications and using dronedarone in these circumstances could cause serious, potentially life-threatening harm:
- Allergy to dronedarone or any of the other ingredients in this medicine (hypromellose, pregelatinised starch, crospovidone, lactose monohydrate, colloidal anhydrous silica, magnesium stearate, macrogol, titanium dioxide).
- Heart block or conduction disorders (atrioventricular block, sinoatrial block) unless you have a functioning pacemaker, as dronedarone may cause very slow heart rates or pauses in heartbeat.
- Very slow resting heart rate (bradycardia below 50 beats per minute) without a pacemaker.
- Prolonged QTc interval on your ECG (greater than 500 milliseconds), as dronedarone may further prolong the QT interval and increase the risk of potentially fatal ventricular arrhythmias such as torsades de pointes.
- Permanent (chronic) atrial fibrillation — when AF has been present for at least 6 months and no decision has been made to attempt restoration of sinus rhythm. The PALLAS trial demonstrated that dronedarone increased cardiovascular events, including stroke and cardiovascular death, in patients with permanent AF.
- Heart failure (current or previous NYHA Class III–IV, or recent decompensated heart failure requiring hospitalization). The ANDROMEDA trial showed increased mortality in patients with severe heart failure treated with dronedarone.
- Left ventricular systolic dysfunction (reduced ejection fraction), as dronedarone may worsen cardiac function.
- Previous lung or liver toxicity related to amiodarone use.
- Concurrent use of strong CYP3A4 inhibitors such as ketoconazole, itraconazole, voriconazole, posaconazole, ritonavir, or nefazodone, as these substantially increase dronedarone blood levels.
- Concurrent use of QT-prolonging drugs including certain antiarrhythmics (sotalol, flecainide, propafenone, quinidine, disopyramide, dofetilide, amiodarone), certain antibiotics (erythromycin, clarithromycin, telithromycin), certain antidepressants (tricyclic antidepressants), phenothiazines, bepridil, cisapride, and terfenadine.
- Concurrent use of dabigatran (an anticoagulant), as dronedarone significantly increases dabigatran levels and bleeding risk.
- Severe hepatic impairment (liver disease).
- Severe renal impairment (creatinine clearance <30 mL/min).
Warnings and Precautions
Talk to your doctor or pharmacist before taking Dronedarone STADA if you have any of the following conditions, as special monitoring or dose adjustments may be needed:
- Low blood potassium or magnesium levels (hypokalaemia, hypomagnesaemia) — these should be corrected before starting dronedarone, as electrolyte imbalances increase the risk of arrhythmias.
- Age over 75 years — limited clinical experience in this population; your doctor will weigh the benefits and risks carefully.
- Coronary artery disease (narrowing of the arteries supplying the heart muscle) — inform your doctor as this may influence treatment decisions.
While taking Dronedarone STADA, notify your doctor immediately if:
- Your atrial fibrillation becomes permanent — dronedarone should be stopped immediately in this case.
- You develop signs of heart failure: swollen feet or legs, difficulty breathing when lying down or sleeping, shortness of breath during physical activity, or unexplained weight gain.
- You develop signs of liver problems: abdominal pain or discomfort, loss of appetite, nausea, vomiting, yellowing of the skin or eyes (jaundice), unusually dark urine, fatigue (especially in combination with the above symptoms), or itching.
- You become short of breath or develop a dry, non-productive cough — these may indicate lung inflammation (interstitial lung disease).
Medical Monitoring During Treatment
Your doctor will perform several tests to monitor your condition and the effects of dronedarone:
- ECG (electrocardiogram) to monitor your heart’s electrical activity, particularly the QT interval. An ECG should be performed before starting treatment, at least every 6 months during treatment, and whenever dose changes are made.
- Liver function blood tests before starting treatment and periodically throughout therapy (typically monthly for the first 6 months, then at 9 and 12 months, and periodically thereafter).
- Kidney function tests — dronedarone may increase blood creatinine levels by approximately 10–15% without actually affecting kidney function. Your doctor will use adjusted reference values when interpreting these results.
- INR monitoring if you take warfarin, as dronedarone can increase the anticoagulant effect of warfarin.
- Lung examination if respiratory symptoms develop.
Inform any healthcare professional who performs blood tests that you are taking Dronedarone STADA, as the elevated creatinine levels may be misinterpreted as kidney impairment.
Pregnancy and Breastfeeding
If you are pregnant, think you may be pregnant, or are planning to become pregnant, consult your doctor before taking this medicine. Dronedarone is not recommended during pregnancy due to potential risks to the unborn child. Animal studies have shown reproductive toxicity, and there are insufficient human data to establish safety. Women of childbearing potential must use effective contraception during treatment. If you become pregnant while taking Dronedarone STADA, stop taking the tablets immediately and contact your doctor.
Breastfeeding is not recommended during treatment with dronedarone. It is not known whether dronedarone or its metabolites pass into breast milk. Given the potential for serious adverse effects in breastfed infants, discuss alternative feeding options with your doctor if treatment with dronedarone is necessary.
Children and Adolescents
Dronedarone STADA is not recommended for use in children and adolescents under 18 years of age. The safety and efficacy of dronedarone in this age group have not been established, and no paediatric clinical trials have been conducted.
Driving and Operating Machinery
Dronedarone STADA does not usually affect your ability to drive or operate machinery. However, if you experience side effects such as fatigue or dizziness, you should avoid driving or operating machinery until the symptoms resolve. You are personally responsible for assessing whether you are fit to drive or perform tasks requiring alertness.
How Does Dronedarone STADA Interact with Other Drugs?
Dronedarone is metabolized primarily by the liver enzyme CYP3A4 and is itself a moderate inhibitor of CYP3A4, CYP2D6, and P-glycoprotein (P-gp). These pharmacokinetic properties give rise to numerous clinically important drug interactions. Always tell your doctor or pharmacist about all medicines you are taking, have recently taken, or might take, including over-the-counter medicines and herbal products.
Drug interactions with dronedarone can be broadly divided into two categories: contraindicated combinations that must never be used together due to the risk of life-threatening adverse effects, and combinations requiring caution, dose adjustment, or enhanced monitoring. Understanding these interactions is critical for the safe use of dronedarone, as many of the patients who take it are also on multiple cardiovascular medications.
Contraindicated Combinations (Must Not Be Used Together)
| Drug / Drug Class | Examples | Reason |
|---|---|---|
| Other antiarrhythmics | Flecainide, propafenone, quinidine, disopyramide, dofetilide, sotalol, amiodarone | Risk of severe arrhythmias and QT prolongation |
| Azole antifungals | Ketoconazole, voriconazole, itraconazole, posaconazole | Strong CYP3A4 inhibition; substantially increases dronedarone levels |
| Macrolide antibiotics | Erythromycin, clarithromycin, telithromycin | CYP3A4 inhibition and QT prolongation |
| HIV protease inhibitors | Ritonavir | Strong CYP3A4 inhibition |
| Tricyclic antidepressants | Amitriptyline, imipramine, nortriptyline | Risk of QT prolongation and cardiac arrhythmias |
| Phenothiazines | Chlorpromazine, thioridazine | QT prolongation risk |
| Other contraindicated drugs | Bepridil, cisapride, terfenadine, nefazodone | QT prolongation and/or CYP3A4 inhibition |
| Dabigatran | Pradaxa | P-gp inhibition by dronedarone increases dabigatran exposure and bleeding risk |
Interactions Requiring Caution or Dose Adjustment
| Drug / Drug Class | Examples | Clinical Advice |
|---|---|---|
| Calcium channel blockers | Verapamil, diltiazem, nifedipine | May cause additive bradycardia and heart block; initiate at low doses with close ECG monitoring |
| Beta-blockers | Metoprolol, propranolol | Additive heart rate lowering; start with low doses; dronedarone increases metoprolol exposure |
| Cardiac glycosides | Digoxin | Dronedarone increases digoxin levels via P-gp inhibition; reduce digoxin dose by 50% and monitor levels |
| Anticoagulants | Warfarin, rivaroxaban, edoxaban, apixaban | Increased anticoagulant effect; monitor INR closely for warfarin; consider dose reduction for DOACs |
| Statins | Simvastatin, lovastatin, atorvastatin, rosuvastatin | Increased statin levels; limit simvastatin to 10 mg/day to reduce myopathy risk |
| Immunosuppressants | Sirolimus, tacrolimus, everolimus, ciclosporin | CYP3A4 and P-gp interactions; monitor drug levels closely and adjust doses |
| CYP3A4 inducers | Rifampicin, phenobarbital, carbamazepine, phenytoin, St John’s wort | May significantly reduce dronedarone levels, potentially decreasing efficacy; avoid combination |
Food and Drink Interactions
Grapefruit juice: Do not drink grapefruit juice while taking Dronedarone STADA. Grapefruit juice is a potent inhibitor of intestinal CYP3A4, and can increase blood levels of dronedarone by up to threefold (approximately 300%). This substantially increases the risk of dose-dependent adverse effects, including cardiac arrhythmias and liver toxicity. Avoid all forms of grapefruit, including whole fruit and juice, during treatment.
Meals: Dronedarone must always be taken with food. Taking dronedarone with a meal increases its bioavailability by approximately 2–4 fold compared to the fasting state. This is because food slows gastric emptying and increases bile secretion, enhancing the dissolution and absorption of the drug. Consistent administration with meals also reduces the variability in drug exposure, leading to more predictable therapeutic levels.
What Is the Correct Dosage of Dronedarone STADA?
Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure. Treatment with Dronedarone STADA should be initiated and supervised by a physician experienced in the treatment of cardiac arrhythmias.
Adults
Standard Adult Dose
The recommended dose is 400 mg twice daily (total daily dose: 800 mg).
- Take one 400 mg tablet with breakfast (morning meal)
- Take one 400 mg tablet with dinner (evening meal)
Swallow the tablet whole with water. The tablet cannot be divided into equal doses. Do not crush or chew the tablet.
There is no dose titration or loading dose required for dronedarone. The same dose (400 mg twice daily) is used throughout treatment. No dose adjustment is necessary based on age, body weight, or mild to moderate renal impairment. However, dronedarone is contraindicated in severe renal impairment (creatinine clearance <30 mL/min) and severe hepatic impairment.
Switching from Amiodarone
If you are switching from amiodarone to Dronedarone STADA, your doctor will carefully manage the transition. Due to amiodarone’s extremely long half-life (40–55 days), significant plasma levels of amiodarone and its active metabolite desethylamiodarone persist for weeks to months after discontinuation. Your doctor will determine the appropriate washout period before starting dronedarone, typically monitoring your ECG and clinical status closely during this transition to prevent additive QT-prolongation effects.
Children and Adolescents
Dronedarone STADA should not be used in patients under 18 years of age. Safety and efficacy have not been established in the paediatric population.
Elderly Patients
No dose adjustment is necessary for elderly patients based on age alone. However, physicians should exercise caution in patients over 75 years due to limited clinical data. Elderly patients may be more susceptible to bradycardia and should be monitored closely, particularly when dronedarone is used in combination with beta-blockers or calcium channel blockers that also lower heart rate.
Missed Dose
If you forget to take a dose, do not take a double dose to make up for the missed one. Simply take the next dose at your regular scheduled time with a meal. Maintaining a consistent daily schedule helps ensure steady drug levels in your bloodstream. If you frequently forget doses, consider using a pill organiser or setting daily reminders on your phone.
Overdose
If you take more dronedarone than you should, or if a child accidentally ingests the medicine, contact your doctor, hospital emergency department, or poison control centre immediately. Take the medicine packaging with you so that healthcare professionals can identify what was taken.
There is no specific antidote for dronedarone overdose. Treatment is supportive and symptomatic. In case of overdose, continuous cardiac monitoring is essential, as bradycardia and QT prolongation may occur. Haemodynamic support and management of arrhythmias should follow standard clinical protocols.
Stopping Treatment
Do not stop taking Dronedarone STADA without first consulting your doctor or pharmacist. Sudden discontinuation may allow atrial fibrillation to recur. Your doctor will advise you on whether and how to stop treatment based on your clinical situation. Due to dronedarone’s relatively short half-life, the drug is eliminated from the body within a few days of stopping.
What Are the Side Effects of Dronedarone STADA?
Like all medicines, this medicine can cause side effects, although not everybody gets them. The following side effects have been reported with dronedarone. If you experience any serious side effects, seek medical attention immediately.
Very Common
May affect more than 1 in 10 people
- Increased blood creatinine levels (a laboratory finding; usually does not reflect actual kidney damage)
- QTc prolongation on ECG (a change in the heart’s electrical pattern that requires monitoring)
- Signs of heart failure in clinical studies (observed at similar rates to placebo): swollen feet or legs, difficulty breathing when lying down, shortness of breath during exertion, weight gain
Common
May affect up to 1 in 10 people
- Diarrhoea
- Nausea
- Vomiting
- Abdominal pain
- Fatigue
- Skin rash or itching
- Slow heart rate (bradycardia)
- Changes in liver function blood tests
Uncommon
May affect up to 1 in 100 people
- Lung inflammation with scarring (interstitial lung disease, including pneumonitis and pulmonary fibrosis) — symptoms include breathlessness and dry cough
- Skin redness or eczema (redness, itching, burning, or blisters)
- Increased sensitivity to sunlight (photosensitivity)
- Taste disturbance (dysgeusia)
Rare
May affect up to 1 in 1,000 people
- Liver damage, including life-threatening hepatic failure — symptoms include abdominal pain, loss of appetite, nausea, vomiting, jaundice (yellowing of skin or eyes), dark urine, fatigue, itching
- Severe allergic reactions including swelling of the face, lips, tongue, or throat (angioedema)
- Loss of taste (ageusia)
- Blood vessel inflammation (vasculitis, including leukocytoclastic vasculitis)
Important Notes on Side Effects
Gastrointestinal effects such as diarrhoea, nausea, and vomiting are among the most common reasons patients discontinue dronedarone therapy. These effects are usually mild to moderate in severity and tend to occur during the first few weeks of treatment, often improving with continued use. Taking the tablets with food as directed can help reduce gastrointestinal discomfort. Persistent vomiting or severe diarrhoea should be reported to your doctor, as dehydration can lead to kidney problems and electrolyte imbalances that may increase the risk of arrhythmias.
Liver monitoring is critical during dronedarone therapy. Cases of severe hepatocellular injury, including acute liver failure requiring transplantation, have been reported in post-marketing surveillance, although these events are rare (estimated at fewer than 1 in 10,000 patients). Your doctor will perform liver function tests before starting treatment and periodically thereafter. The EMA and FDA have issued specific guidance on hepatic monitoring schedules. Report any unexplained symptoms of liver injury immediately to your doctor.
Creatinine elevation: Dronedarone inhibits the tubular secretion of creatinine via organic cation transporter 2 (OCT2), which increases serum creatinine by approximately 10–15% without affecting the actual glomerular filtration rate. This is a pharmacological effect, not a sign of kidney damage. However, if your creatinine levels rise significantly beyond this expected increase, your doctor may investigate further to rule out true renal impairment.
Pulmonary toxicity: Unlike amiodarone, which carries a significant risk of pulmonary fibrosis (1–17% of patients), dronedarone has a much lower incidence of lung toxicity. Nevertheless, cases of interstitial lung disease have been reported. If you develop new or worsening breathlessness or a persistent dry cough, your doctor should investigate with chest imaging and pulmonary function tests.
How Should You Store Dronedarone STADA?
Keep this medicine out of the sight and reach of children at all times. Children should never have unsupervised access to medications, as accidental ingestion of cardiovascular drugs can cause serious harm.
Do not use this medicine after the expiry date which is stated on the blister pack and carton after “EXP.” The expiry date refers to the last day of that month. No special storage conditions are required for Dronedarone STADA — store at room temperature, away from direct heat and moisture.
Do not use this medicine if you notice any visible signs of deterioration, such as discoloration, crumbling, or damage to the tablets or packaging. Inspect the blister pack before each use to ensure the packaging is intact.
Do not dispose of medicines via wastewater or household waste. Ask your pharmacist how to dispose of medicines you no longer use. These measures help protect the environment and prevent accidental exposure to others.
What Does Dronedarone STADA Contain?
Active Substance
Each film-coated tablet contains 400 mg dronedarone (as dronedarone hydrochloride). Dronedarone hydrochloride is the salt form of the active substance, which dissociates to release dronedarone after dissolution in the gastrointestinal tract. The molecular formula of dronedarone hydrochloride is C31H44BrNO3S·HCl, and it has a molecular weight of approximately 593.2 g/mol.
Other Ingredients
Tablet core: hypromellose (E464), pregelatinised starch, crospovidone (a disintegrant that helps the tablet break apart in the stomach), lactose monohydrate, colloidal anhydrous silica (E551), magnesium stearate (E470b).
Film coating: hypromellose (E464), macrogol (E1521), titanium dioxide (E171). The film coating protects the tablet core, aids swallowing, and contributes to the white appearance of the tablet.
Appearance and Pack Sizes
Dronedarone STADA is a white, oblong film-coated tablet measuring approximately 17.6 × 8.1 mm. The tablets are available in blister packs or perforated unit-dose blister packs (opaque PVC/Aluminium or opaque PVC/PE/PVDC-Aluminium) in the following pack sizes: 20, 20×1, 50, 50×1, 60, 60×1, 100, and 100×1 tablets. Not all pack sizes may be marketed in every country.
Manufacturer
Dronedarone STADA is manufactured by STADA Arzneimittel AG, Stadastrasse 2–18, 61118 Bad Vilbel, Germany. Additional manufacturing is performed by Rontis Hellas Medical and Pharmaceutical Products S.A. in Larisa, Greece. The local representative in the Nordic region is STADA Nordic ApS, Marielundvej 46A, 2730 Herlev, Denmark.
Frequently Asked Questions About Dronedarone STADA
Dronedarone STADA is used to maintain normal heart rhythm (sinus rhythm) in adults whose atrial fibrillation has been corrected through cardioversion. It helps prevent the recurrence of irregular heartbeat. It is not suitable for patients with permanent atrial fibrillation or heart failure.
Dronedarone is structurally related to amiodarone but lacks the iodine moiety. This gives it a much shorter half-life (13–19 hours vs. 40–55 days for amiodarone) and significantly reduces the risk of thyroid dysfunction, pulmonary fibrosis, and corneal microdeposits. However, dronedarone is less potent as an antiarrhythmic and is not suitable for patients with heart failure, where amiodarone may still be the preferred choice.
No. Grapefruit juice inhibits the CYP3A4 enzyme and can increase blood levels of dronedarone by up to threefold. This substantially raises the risk of adverse effects, including cardiac arrhythmias and liver problems. You should avoid all forms of grapefruit and grapefruit juice while taking dronedarone.
Taking dronedarone with food increases its absorption (bioavailability) by 2–4 fold compared to taking it on an empty stomach. Without food, the drug levels in your blood may be too low to be effective. Always take your tablets with breakfast and with your evening meal to ensure consistent and adequate drug exposure.
If you miss a dose, do not take a double dose to make up for it. Simply take the next dose at your regular time with a meal. Dronedarone has a relatively short half-life, so maintaining your regular dosing schedule is important. If you frequently forget doses, consider setting reminders or using a pill organiser.
The most serious risks include liver damage (including rare cases of life-threatening liver failure), worsening or new-onset heart failure, lung inflammation with scarring (interstitial lung disease), and severe allergic reactions. The PALLAS trial showed that dronedarone increased cardiovascular events in patients with permanent AF, which is why it is contraindicated in this population. Regular monitoring of liver function, heart function, and lung health is essential throughout treatment.
References and Sources
This article is based on the following evidence-based sources. All medical information has been reviewed according to international guidelines and the GRADE evidence framework.
- European Medicines Agency (EMA). Summary of Product Characteristics: Dronedarone Hydrochloride (MULTAQ). EMA/CHMP, latest revision. www.ema.europa.eu
- Hohnloser SH, Crijns HJGM, van Eickels M, et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. New England Journal of Medicine. 2009;360(7):668–678. doi:10.1056/NEJMoa0803778 (ATHENA trial)
- Connolly SJ, Camm AJ, Halperin JL, et al. Dronedarone in high-risk permanent atrial fibrillation. New England Journal of Medicine. 2011;365(24):2268–2276. doi:10.1056/NEJMoa1109867 (PALLAS trial)
- Köber L, Torp-Pedersen C, McMurray JJV, et al. Increased mortality after dronedarone therapy for severe heart failure. New England Journal of Medicine. 2008;358(25):2678–2687. doi:10.1056/NEJMoa0800456 (ANDROMEDA trial)
- Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation. European Heart Journal. 2021;42(5):373–498. doi:10.1093/eurheartj/ehaa612
- Van Gelder IC, Rienstra M, Bunting KV, et al. 2024 ESC Guidelines for the management of atrial fibrillation. European Heart Journal. 2024;45(36):3314–3414. doi:10.1093/eurheartj/ehae176
- January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS focused update of the 2014 guideline for management of patients with atrial fibrillation. Circulation. 2019;140(2):e125–e151.
- British National Formulary (BNF). Dronedarone. NICE Evidence Services. bnf.nice.org.uk
- World Health Organization (WHO). WHO Model List of Essential Medicines – 23rd List, 2023. Geneva: World Health Organization.
- U.S. Food and Drug Administration (FDA). MULTAQ (dronedarone) Label. FDA Approved Drug Products. www.accessdata.fda.gov
Medical Editorial Team
This article has been written and reviewed by the iMedic Medical Editorial Team, comprising licensed specialist physicians in cardiology and clinical pharmacology.
Medical Review Board
Board-certified cardiologists and clinical pharmacologists with expertise in antiarrhythmic drug therapy. All content follows ESC, AHA, EMA, and FDA guidelines.
Evidence Standards
All medical claims are supported by Level 1A evidence (systematic reviews and meta-analyses of randomized controlled trials) following the GRADE evidence framework.
Our editorial process ensures accuracy and independence. We maintain no financial relationships with pharmaceutical companies. Learn more about our editorial standards and medical team.